

Sepsis Diagnostics Market Size By Technology (Microbiology, PCR, Immunoassay, microfluidics, Biomarker), Product (Media, Reagent, Instrument), Method (Automated), Test (Lab, POC), Pathogen (Bacterial, Fungal), End User & Region - Global Forecast to 2029

Market Report | 2024-04-08 | 264 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global sepsis diagnostics market is projected to reach USD 890 million by 2029 from USD 634 million in 2024, growing at a CAGR of 7.0% during the forecast period. The increasing number of sepsis diagnostics procedures is one of the major factors anticipated to boost market growth in the forecasting years. Additionally, the high cost of diagnostic devices affects the growth of the sepsis diagnostics market.

"The blood culture segment to hold the largest share of the market in 2024."

Based on technology, sepsis diagnostics is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. Blood culture segment is expected to dominate the sepsis diagnostics market during the forecast period. With the increasing sepsis incidences and this technique be the standard technique leading to the growth of this market segment.

"The blood culture media segment to hold the largest share of the market in 2024."

Based on product, the sepsis diagnostics market is segmented into mesh, sutures, mesh fixator, and other products. The sepsis diagnostics market is expected to be dominated by blood culture media segment during the forecast period. The blood culture media is expected to grow due to their affordable prices as compared to other sepsis diagnostics products.

"The bacterial sepsis segment to hold the largest share of the market in 2024."

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Based on the pathogen type, the sepsis diagnostics market is segmented into bacterial sepsis, fungal sepsis, and other pathogens. The bacterial sepsis segment is further divided into gram-positive bacteria sepsis and gram-negative bacteria sepsis. The bacterial sepsis segment is estimated to hold the largest market share of the sepsis diagnostics market during the forecast period. Rising number of bacterial sepsis cases leads to the increasing growth of the segment in the market.

"The hospitals & speciality clinics segment to hold the largest share of the market in 2024."

The end user market is segmented into hospitals & speciality clinics, pathology & reference laboratories, and research laboratories, academic institutes & CROs . Hospitals & speciality clinics accounted for the largest share of the global sepsis diagnostics market in 2023 during the forecasted years. This can be attributed to the high patient inflow in this care setting. Only hospitals and clinics can provide the care and monitoring required in exceptionally severe cases, which also accounts for their dominance in the market.

"The market in the North America region is expected to hold a significant market share for sepsis diagnostics in 2022."

The sepsis diagnostics market covers five key geographies-North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2023, a significant market share for sepsis diagnostics was held by the market in the North American region, comprising the US and Canada. The strong demand for and adoption of sepsis diagnostics in the US led to the growth of the Sepsis diagnostics market in this region.

A breakdown of the primary participants referred to for this report is provided below:

-□By Company Type: Tier 1- 25%, Tier 2- 30%, and Tier 3- 45%

-□By Designation: C-level- 26%, Directors- 30%, and Others- 44%

-□By Region: North America- 40%, Europe- 31%, Asia Pacific- 20%, Latin America- 6%, MEA- 3%

The prominent players in the sepsis diagnostics market are bioMerieux S.A. (France), Becton Dickinson and Company (US), Danaher Corporation (US), T2 Biosystems (US), QIAGEN N.V. (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific (US), Bruker Corporation (US), Abbott Laboratories (US), among others.

Research Coverage

This report studies the sepsis diagnostics market based on technology, product, method, pathogen type, test type, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

This report provides insights on the following pointers:

-□Analysis of key drivers (High incidence of sepsis, Rising incidence of hospital-acquired infections (HAIs), Growing funding for sepsis-related research), restraints (High cost of automated diagnostic devices), opportunities (Development of rapid diagnostic/POC techniques for early sepsis diagnosis, Evolution of novel biomarkers for sepsis diagnosis, Growth Opportunities in emerging economies), and challenges (Lack of awareness and limited protocols for sepsis diagnosis, Shortage of skilled healthcare professionals) influencing the growth of the sepsis diagnostics market

-□Market Penetration: Comprehensive information on the product portfolios offered by the top players in the sepsis diagnostics market

-□Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and service developments in the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- sepsis diagnostics market
- Market Development: Comprehensive information on lucrative emerging regions
 - Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the sepsis diagnostics market
 - Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and services of the leading market players.

Table of Contents:

1 INTRODUCTION 39

1.1 STUDY OBJECTIVES 39

1.2 MARKET DEFINITION 39

1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY 40

1.3 STUDY SCOPE 41

1.3.1 MARKETS COVERED 41

1.3.2 GEOGRAPHIES COVERED 41

1.3.3 YEARS CONSIDERED 42

1.4 CURRENCY 42

1.5 MARKET STAKEHOLDERS 42

1.6 SUMMARY OF CHANGES 43

1.6.1 RECESSION IMPACT 43

2 RESEARCH METHODOLOGY 45

2.1 RESEARCH DATA 45

FIGURE 1 RESEARCH DESIGN 45

2.1.1 SECONDARY DATA 46

2.1.1.1 Indicative list of secondary sources 47

2.1.2 PRIMARY DATA 47

FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 48

2.2 MARKET ESTIMATION METHODOLOGY 49

FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 49

2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 50

FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2023) 51

2.2.2 APPROACH 1: PROCEDURE-BASED MARKET ESTIMATION 51

FIGURE 5 MARKET SIZE ESTIMATION: SEPSIS DIAGNOSTICS MARKET BASED ON PROCEDURE METHODOLOGY 51

2.2.3 APPROACH 2: END USER-BASED MARKET ESTIMATION 52

FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: SEPSIS DIAGNOSTICS MARKET 52

2.2.4 PRIMARY RESEARCH VALIDATION 53

2.3 DATA TRIANGULATION 54

FIGURE 7 DATA TRIANGULATION METHODOLOGY 54

2.4 RESEARCH ASSUMPTIONS 55

2.5 RESEARCH LIMITATIONS 55

2.6 RISK ASSESSMENT 56

TABLE 1 SEPSIS DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS 56

2.6.1 IMPACT OF RECESSION ON SEPSIS DIAGNOSTICS MARKET 56

?

3 EXECUTIVE SUMMARY 57

FIGURE 8 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION) 57

FIGURE 9 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION) 58

| | | |
|-----------|------------------------------------------------------------------------------------------|----|
| FIGURE 10 | SEPSIS DIAGNOSTICS MARKET SHARE, BY METHOD, 2024 VS. 2029 | 58 |
| FIGURE 11 | SEPSIS DIAGNOSTICS MARKET SHARE, BY TEST TYPE, 2024 VS. 2029 | 59 |
| FIGURE 12 | SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024 VS. 2029 (USD MILLION) | 59 |
| FIGURE 13 | SEPSIS DIAGNOSTICS MARKET SHARE, BY END USER, 2024 VS. 2029 | 60 |
| FIGURE 14 | GEOGRAPHICAL SNAPSHOT OF SEPSIS DIAGNOSTICS MARKET | 60 |
| 4 | PREMIUM INSIGHTS | 62 |
| 4.1 | SEPSIS DIAGNOSTICS MARKET OVERVIEW | 62 |
| FIGURE 15 | HIGH INCIDENCE OF SEPSIS TO DRIVE MARKET | 62 |
| 4.2 | ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT AND COUNTRY (2023) | 63 |
| FIGURE 16 | BLOOD CULTURE MEDIA SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023 | 63 |
| 4.3 | SEPSIS DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES | 64 |
| FIGURE 17 | CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD | 64 |
| 4.4 | SEPSIS DIAGNOSTICS MARKET: REGIONAL MIX, 2022-2029 (USD MILLION) | 64 |
| FIGURE 18 | NORTH AMERICA WILL CONTINUE TO DOMINATE SEPSIS DIAGNOSTICS MARKET DURING FORECAST PERIOD | 64 |
| 5 | MARKET OVERVIEW | 65 |
| 5.1 | INTRODUCTION | 65 |
| 5.2 | MARKET DYNAMICS | 65 |
| FIGURE 19 | SEPSIS DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES | 65 |
| 5.2.1 | DRIVERS | 66 |
| 5.2.1.1 | High incidence of sepsis | 66 |
| 5.2.1.2 | Rising incidence of HAIs | 67 |
| 5.2.1.3 | Growing funding for sepsis-related research | 67 |
| 5.2.2 | RESTRAINTS | 68 |
| 5.2.2.1 | High cost of automated diagnostic devices | 68 |
| 5.2.3 | OPPORTUNITIES | 68 |
| 5.2.3.1 | Development of rapid diagnostic/POC techniques for early sepsis diagnosis | 68 |
| 5.2.3.2 | Evolution of novel biomarkers for sepsis diagnosis | 68 |
| 5.2.3.3 | Growth opportunities in emerging economies | 69 |
| 5.2.4 | CHALLENGES | 69 |
| 5.2.4.1 | Lack of awareness and limited protocols for sepsis diagnosis | 69 |
| 5.2.4.2 | Shortage of skilled healthcare professionals | 70 |
| | ? | |
| 5.3 | REGULATORY SCENARIO | 70 |
| 5.3.1 | REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS | 70 |
| TABLE 2 | NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS | 70 |
| TABLE 3 | EUROPE: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS | 71 |
| TABLE 4 | ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS | 71 |
| TABLE 5 | LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS | 72 |
| TABLE 6 | MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS | 72 |
| 5.3.2 | KEY REGULATORY GUIDELINES | 72 |
| 5.3.2.1 | North America | 72 |
| 5.3.2.1.1 | US | 72 |
| 5.3.2.1.2 | Canada | 73 |
| 5.3.2.2 | Europe | 73 |
| 5.3.2.3 | Asia Pacific | 73 |
| 5.3.2.3.1 | China | 73 |
| 5.3.2.3.2 | Japan | 74 |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | |
|-----------|-----------------------------------------------------------------------------|----|
| 5.3.2.3.3 | India | 74 |
| 5.3.2.4 | Latin America | 74 |
| 5.4 | REIMBURSEMENT SCENARIO | 74 |
| TABLE 7 | MS DRG PAYMENT CALCULATED FOR NATIONAL PROVIDERS | 75 |
| 5.5 | VALUE CHAIN ANALYSIS | 75 |
| 5.5.1 | RESEARCH & DEVELOPMENT | 76 |
| 5.5.2 | PROCUREMENT AND PRODUCT DEVELOPMENT | 76 |
| 5.5.3 | MARKETING, SALES, AND DISTRIBUTION | 76 |
| FIGURE 20 | VALUE CHAIN ANALYSIS | 76 |
| 5.6 | SUPPLY CHAIN ANALYSIS | 77 |
| 5.6.1 | PROMINENT COMPANIES | 77 |
| 5.6.2 | SMALL & MEDIUM-SIZED ENTERPRISES | 77 |
| 5.6.3 | END USERS | 77 |
| FIGURE 21 | SUPPLY CHAIN ANALYSIS | 77 |
| 5.7 | ECOSYSTEM COVERAGE | 78 |
| FIGURE 22 | MARKET MAP | 78 |
| 5.8 | PORTER'S FIVE FORCES ANALYSIS | 79 |
| TABLE 8 | SEPSIS DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS | 79 |
| 5.8.1 | INTENSITY OF COMPETITIVE RIVALRY | 79 |
| 5.8.2 | BARGAINING POWER OF BUYERS | 79 |
| 5.8.3 | BARGAINING POWER OF SUPPLIERS | 79 |
| 5.8.4 | THREAT OF NEW ENTRANTS | 80 |
| 5.8.5 | THREAT OF SUBSTITUTES | 80 |
| 5.9 | TRADE DATA ANALYSIS | 80 |
| TABLE 9 | IMPORT DATA FOR HERNIA MESH (HS CODE 902190), BY COUNTRY, 2018-2022 (USD) | 80 |
| TABLE 10 | EXPORT DATA FOR HERNIA MESHES (HS CODE 902190), BY COUNTRY, 2018-2022 (USD) | 81 |
| 5.10 | PATENT ANALYSIS | 82 |
| FIGURE 23 | PATENT ANALYSIS | 82 |
| 5.11 | PRICING ANALYSIS | 83 |
| 5.11.1 | AVERAGE SELLING PRICE TREND, BY REGION | 83 |
| TABLE 11 | SEPSIS DIAGNOSTICS PRICING ANALYSIS, BY REGION, 2023 (USD) | 83 |
| 5.11.2 | AVERAGE SELLING PRICE TREND, BY KEY PLAYER | 83 |
| TABLE 12 | HERNIA REPAIR PRICING ANALYSIS, BY KEY PLAYER, 2023 (USD) | 83 |
| 5.12 | TECHNOLOGY ANALYSIS | 84 |
| 5.12.1 | KEY TECHNOLOGIES | 84 |
| 5.12.1.1 | Biomarkers | 84 |
| 5.12.1.2 | Microfluidics | 84 |
| 5.12.2 | COMPLIMENTARY TECHNOLOGIES | 84 |
| 5.12.2.1 | Genomics and Transcriptomics | 84 |
| 5.12.2.2 | Machine Learning and Artificial Intelligence (AI) | 84 |
| 5.12.3 | ADJACENT TECHNOLOGIES | 84 |
| 5.12.3.1 | Nanotechnology Sensors | 84 |
| 5.12.3.2 | Medical Imaging | 84 |
| 5.12.3.3 | Digital Health Solutions | 84 |
| 5.13 | KEY CONFERENCES AND EVENTS IN 2023-2024 | 85 |
| TABLE 13 | SEPSIS DIAGNOSTICS: LIST OF MAJOR CONFERENCES & EVENTS | 85 |
| 5.14 | TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS | 86 |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | |
|-----------|----------------------------------------------------------------------------------------------|-----|
| FIGURE 24 | EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX | 86 |
| 5.15 | SEPSIS DIAGNOSTICS MARKET: RECESSION IMPACT | 86 |
| 5.16 | KEY STAKEHOLDERS AND BUYING CRITERIA | 87 |
| 5.16.1 | KEY STAKEHOLDERS | 87 |
| FIGURE 25 | INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS | 87 |
| TABLE 14 | INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCT SEGMENTS (%) | 87 |
| 5.16.2 | KEY BUYING CRITERIA | 87 |
| FIGURE 26 | KEY BUYING CRITERIA FOR SEPSIS DIAGNOSTIC PRODUCTS | 87 |
| TABLE 15 | KEY BUYING CRITERIA FOR SEPSIS DIAGNOSTIC PRODUCTS | 88 |
| 5.17 | UNMET NEEDS AND KEY PAIN POINTS | 88 |
| TABLE 16 | SEPSIS DIAGNOSTICS MARKET: UNMET CUSTOMER NEEDS AND KEY PAIN POINTS | 88 |
| 5.18 | INVESTMENT SCENARIO | 89 |
| FIGURE 27 | NUMBER OF INVESTOR DEALS IN SEPSIS DIAGNOSTICS MARKET, BY KEY PLAYER, 2018-2022 | 89 |
| FIGURE 28 | VALUE OF INVESTOR DEALS IN SEPSIS DIAGNOSTICS MARKET, BY KEY PLAYER, 2018-2022 (USD MILLION) | 89 |
| 6 | SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY | 90 |
| 6.1 | INTRODUCTION | 91 |
| TABLE 17 | SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 91 |
| 6.2 | BLOOD CULTURE (MICROBIOLOGY TESTING) | 91 |
| 6.2.1 | MOST COMMONLY ADOPTED TECHNOLOGY FOR SEPSIS DIAGNOSTICS | 91 |
| TABLE 18 | BLOOD CULTURE MARKET, BY REGION, 2022-2029 (USD MILLION) | 92 |
| TABLE 19 | BLOOD CULTURE MARKET, BY PRODUCT, 2022-2029 (USD MILLION) | 92 |
| TABLE 20 | BLOOD CULTURE MARKET, BY METHOD, 2022-2029 (USD MILLION) | 92 |
| TABLE 21 | BLOOD CULTURE MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION) | 93 |
| TABLE 22 | BLOOD CULTURE MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022-2029 (USD MILLION) | 93 |
| TABLE 23 | BLOOD CULTURE MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) | 93 |
| TABLE 24 | BLOOD CULTURE MARKET, BY END USER, 2022-2029 (USD MILLION) | 94 |
| 6.3 | IMMUNOASSAYS | 94 |
| 6.3.1 | RIISING PRODUCT DEVELOPMENT BY MAJOR PLAYERS TO SUPPORT MARKET GROWTH | 94 |
| TABLE 25 | IMMUNOASSAYS MARKET, BY REGION, 2022-2029 (USD MILLION) | 95 |
| TABLE 26 | IMMUNOASSAYS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) | 95 |
| TABLE 27 | IMMUNOASSAYS MARKET, BY METHOD, 2022-2029 (USD MILLION) | 95 |
| TABLE 28 | IMMUNOASSAYS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION) | 96 |
| TABLE 29 | IMMUNOASSAYS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022-2029 (USD MILLION) | 96 |
| TABLE 30 | IMMUNOASSAYS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) | 96 |
| TABLE 31 | IMMUNOASSAYS MARKET, BY END USER, 2022-2029 (USD MILLION) | 97 |
| 6.4 | MOLECULAR DIAGNOSTICS | 97 |
| TABLE 32 | MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 97 |
| TABLE 33 | MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2022-2029 (USD MILLION) | 98 |
| TABLE 34 | MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) | 98 |
| TABLE 35 | MOLECULAR DIAGNOSTICS MARKET, BY METHOD, 2022-2029 (USD MILLION) | 98 |
| TABLE 36 | MOLECULAR DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION) | 99 |
| TABLE 37 | MOLECULAR DIAGNOSTICS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022-2029 (USD MILLION) | 99 |
| TABLE 38 | MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) | 99 |
| TABLE 39 | MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) | 100 |
| 6.4.1 | POLYMERASE CHAIN REACTION | 100 |
| 6.4.1.1 | Quick turnaround time and technological advancements to propel market | 100 |
| TABLE 40 | POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022-2029 (USD MILLION) | 100 |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | |
|----------|---------------------------------------------------------------------------------------------------|-----|
| 6.4.2 | MICROARRAYS | 101 |
| 6.4.2.1 | Simultaneous analysis capabilities & accuracy to boost adoption | 101 |
| TABLE 41 | MICROARRAYS MARKET, BY REGION, 2022-2029 (USD MILLION) | 101 |
| 6.4.3 | PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION | 101 |
| 6.4.3.1 | Enables rapid diagnosis of bloodstream infections | 101 |
| TABLE 42 | PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2022-2029 (USD MILLION) | 102 |
| 6.4.4 | DNA SEQUENCING | 102 |
| 6.4.4.1 | Shortens time for sepsis diagnosis | 102 |
| TABLE 43 | DNA SEQUENCING MARKET, BY REGION, 2022-2029 (USD MILLION) | 103 |
| 6.5 | FLOW CYTOMETRY | 103 |
| 6.5.1 | LACK OF STANDARDIZED PROTOCOLS?KEY FACTOR RESTRAINING MARKET GROWTH | 103 |
| TABLE 44 | FLOW CYTOMETRY MARKET, BY REGION, 2022-2029 (USD MILLION) | 103 |
| TABLE 45 | FLOW CYTOMETRY MARKET, BY PRODUCT, 2022-2029 (USD MILLION) | 104 |
| TABLE 46 | FLOW CYTOMETRY MARKET, BY METHOD, 2022-2029 (USD MILLION) | 104 |
| TABLE 47 | FLOW CYTOMETRY MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION) | 104 |
| TABLE 48 | FLOW CYTOMETRY MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022-2029 (USD MILLION) | 105 |
| TABLE 49 | FLOW CYTOMETRY MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) | 105 |
| TABLE 50 | FLOW CYTOMETRY MARKET, BY END USER, 2022-2029 (USD MILLION) | 105 |
| 6.6 | MICROFLUIDICS | 106 |
| 6.6.1 | RIISING ADOPTION OF ADVANCED AND RAPID TESTING TO DRIVE GROWTH | 106 |
| TABLE 51 | MICROFLUIDICS MARKET, BY REGION, 2022-2029 (USD MILLION) | 106 |
| TABLE 52 | MICROFLUIDICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) | 107 |
| TABLE 53 | MICROFLUIDICS MARKET, BY METHOD, 2022-2029 (USD MILLION) | 107 |
| TABLE 54 | MICROFLUIDICS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION) | 107 |
| TABLE 55 | MICROFLUIDICS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022-2029 (USD MILLION) | 108 |
| TABLE 56 | MICROFLUIDICS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) | 108 |
| TABLE 57 | MICROFLUIDICS MARKET, BY END USER, 2022-2029 (USD MILLION) | 108 |
| 6.7 | BIOMARKERS | 109 |
| 6.7.1 | RESEARCH & DEVELOPMENT FOR DISCOVERY OF NOVEL BIOMARKERS TO DRIVE GROWTH | 109 |
| TABLE 58 | BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION) | 109 |
| TABLE 59 | BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) | 110 |
| TABLE 60 | BIOMARKERS MARKET, BY METHOD, 2022-2029 (USD MILLION) | 110 |
| TABLE 61 | BIOMARKERS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION) | 110 |
| TABLE 62 | BIOMARKERS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022-2029 (USD MILLION) | 111 |
| TABLE 63 | BIOMARKERS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) | 111 |
| TABLE 64 | BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION) | 111 |
| 7 | SEPSIS DIAGNOSTICS MARKET, BY PRODUCT | 112 |
| 7.1 | INTRODUCTION | 113 |
| TABLE 65 | SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) | 113 |
| 7.2 | BLOOD CULTURE MEDIA | 113 |
| 7.2.1 | RISE IN BLOODSTREAM INFECTIONS TO DRIVE GROWTH | 113 |
| TABLE 66 | SEPSIS DIAGNOSTIC BLOOD CULTURE MEDIA MARKET, BY REGION, 2022-2029 (USD MILLION) | 114 |
| 7.3 | ASSAYS & REAGENT KITS | 114 |
| 7.3.1 | ASSAYS BETTER ENABLE ANALYSIS OF PATIENT SAMPLES FOR DISEASE DIAGNOSIS | 114 |
| TABLE 67 | SEPSIS DIAGNOSTIC ASSAYS & REAGENT KITS MARKET, BY REGION, 2022-2029 (USD MILLION) | 115 |
| 7.4 | INSTRUMENTS | 115 |
| 7.4.1 | INCREASING INCLINATION TOWARD RAPID DIAGNOSTIC SYSTEMS TO DRIVE MARKET | 115 |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | |
|----------|---------------------------------------------------------------------------------------------------|-----|
| TABLE 68 | SEPSIS DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2022-2029 (USD MILLION) | 116 |
| 7.5 | SOFTWARE | 116 |
| 7.5.1 | INCREASING USE OF AUTOMATED INSTRUMENTS TO DRIVE DEMAND FOR SOFTWARE | 116 |
| TABLE 69 | SEPSIS DIAGNOSTIC SOFTWARE MARKET, BY REGION, 2022-2029 (USD MILLION) | 117 |
| 8 | SEPSIS DIAGNOSTICS MARKET, BY METHOD | 118 |
| 8.1 | INTRODUCTION | 119 |
| TABLE 70 | SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022-2029 (USD MILLION) | 119 |
| 8.2 | CONVENTIONAL DIAGNOSTICS | 119 |
| 8.2.1 | EASE OF USE AND LOW COST TO PROPEL MARKET GROWTH | 119 |
| TABLE 71 | CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022-2029 (USD MILLION) | 120 |
| 8.3 | AUTOMATED DIAGNOSTICS | 120 |
| 8.3.1 | ACCURACY AND QUICK TURNAROUND TIME TO DRIVE ADOPTION | 120 |
| TABLE 72 | AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022-2029 (USD MILLION) | 121 |
| 9 | SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE | 122 |
| 9.1 | INTRODUCTION | 123 |
| TABLE 73 | SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION) | 123 |
| 9.2 | BACTERIAL SEPSIS | 123 |
| TABLE 74 | BACTERIAL SEPSIS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 123 |
| TABLE 75 | BACTERIAL SEPSIS MARKET, BY REGION, 2022-2029 (USD MILLION) | 124 |
| 9.2.1 | GRAM-NEGATIVE BACTERIAL SEPSIS | 124 |
| 9.2.1.1 | Increasing demand for sepsis diagnostic tests to drive market | 124 |
| TABLE 76 | GRAM-NEGATIVE BACTERIAL CAUSES IN ADULTS | 125 |
| TABLE 77 | GRAM-NEGATIVE BACTERIAL SEPSIS MARKET, BY REGION, 2022-2029 (USD MILLION) | 125 |
| 9.2.2 | GRAM-POSITIVE BACTERIAL SEPSIS | 125 |
| 9.2.2.1 | Increasing incidence of gram-positive nosocomial infections to propel market | 125 |
| TABLE 78 | GRAM-POSITIVE BACTERIAL CAUSES IN ADULTS | 126 |
| TABLE 79 | GRAM-POSITIVE BACTERIAL SEPSIS MARKET, BY REGION, 2022-2029 (USD MILLION) | 126 |
| 9.3 | FUNGAL SEPSIS | 126 |
| 9.3.1 | RISING INCIDENCE OF FUNGAL INFECTIONS TO PROPEL MARKET | 126 |
| TABLE 80 | FUNGAL SEPSIS MARKET, BY REGION, 2022-2029 (USD MILLION) | 127 |
| 9.4 | OTHER PATHOGEN TYPES | 127 |
| TABLE 81 | OTHER PATHOGEN TYPES MARKET, BY REGION, 2022-2029 (USD MILLION) | 127 |
| 10 | SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE | 128 |
| 10.1 | INTRODUCTION | 129 |
| TABLE 82 | SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) | 129 |
| 10.2 | LABORATORY TESTS | 129 |
| 10.2.1 | MOST COMMON AND PREFERRED MODE OF TESTING | 129 |
| TABLE 83 | LABORATORY SEPSIS DIAGNOSTIC TESTS MARKET, BY REGION, 2022-2029 (USD MILLION) | 130 |
| 10.3 | POINT-OF-CARE TESTS | 130 |
| 10.3.1 | INCREASING DEVELOPMENT OF NOVEL POC DIAGNOSTICS TO SUPPORT MARKET GROWTH | 130 |
| TABLE 84 | POINT-OF-CARE SEPSIS DIAGNOSTIC TESTS MARKET, BY REGION, 2022-2029 (USD MILLION) | 131 |
| 11 | SEPSIS DIAGNOSTICS MARKET, BY END USER | 132 |
| 11.1 | INTRODUCTION | 133 |
| TABLE 85 | SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) | 133 |
| 11.2 | HOSPITALS AND SPECIALTY CLINICS | 133 |
| 11.2.1 | INCREASING ADOPTION OF SEPSIS DIAGNOSTIC PRODUCTS BY IN-HOUSE HOSPITAL LABS TO DRIVE MARKET | 133 |
| TABLE 86 | SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS AND SPECIALTY CLINICS, BY REGION, 2022-2029 (USD MILLION) | 134 |

11.3 PATHOLOGY AND REFERENCE LABORATORIES 134

11.3.1 INDEPENDENT LABORATORIES OFFER AFFORDABLE AND EFFICIENT DIAGNOSTIC SERVICES 134

TABLE 87 SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY AND REFERENCE LABORATORIES, BY REGION, 2022-2029 (USD MILLION) 135

11.4 RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS 135

11.4.1 GOVERNMENT SUPPORT AND RISING AWARENESS FOR EARLY SEPSIS DETECTION TO DRIVE GROWTH 135

TABLE 88 SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY REGION, 2022-2029 (USD MILLION) 136

12 SEPSIS DIAGNOSTICS MARKET, BY REGION 137

12.1 INTRODUCTION 138

TABLE 89 SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022-2029 (USD MILLION) 138

12.2 NORTH AMERICA 138

FIGURE 29 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SNAPSHOT 139

TABLE 90 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 139

TABLE 91 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 140

TABLE 92 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 140

TABLE 93 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 141

TABLE 94 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022-2029 (USD MILLION) 141

TABLE 95 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION) 141

TABLE 96 NORTH AMERICA: BACTERIAL SEPSIS MARKET, BY TYPE, 2022-2029 (USD MILLION) 142

TABLE 97 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) 142

TABLE 98 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) 142

12.3 RECESSION IMPACT ON NORTH AMERICAN SEPSIS DIAGNOSTICS MARKET 143

12.3.1 US 143

12.3.1.1 Rising incidence of HAIs to drive demand 143

TABLE 99 US: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 144

TABLE 100 US: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 144

12.3.2 CANADA 145

12.3.2.1 Growing availability of sepsis diagnostic products to support market growth 145

TABLE 101 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 146

TABLE 102 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 146

12.4 EUROPE 146

TABLE 103 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 147

TABLE 104 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 147

TABLE 105 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 148

TABLE 106 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 148

TABLE 107 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022-2029 (USD MILLION) 148

TABLE 108 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION) 149

TABLE 109 EUROPE: BACTERIAL SEPSIS MARKET, BY TYPE, 2022-2029 (USD MILLION) 149

TABLE 110 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) 149

TABLE 111 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) 150

12.4.1 RECESSION IMPACT ON EUROPEAN SEPSIS DIAGNOSTICS MARKET 150

12.4.2 GERMANY 150

12.4.2.1 Adoption of technologically advanced diagnostic products to drive market 150

TABLE 112 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 151

TABLE 113 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 152

12.4.3 UK 152

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | |
|-----------|----------------------------------------------------------------------------------------|-----|
| 12.4.3.1 | Stringent government regulations to drive market growth | 152 |
| TABLE 114 | UK: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 153 |
| TABLE 115 | UK: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 153 |
| 12.4.4 | FRANCE | 153 |
| 12.4.4.1 | High incidence of sepsis to propel growth | 153 |
| TABLE 116 | FRANCE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 154 |
| TABLE 117 | FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 154 |
| 12.4.5 | ITALY | 154 |
| 12.4.5.1 | Supportive government initiatives for raising awareness on sepsis to drive market | 154 |
| TABLE 118 | ITALY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 155 |
| TABLE 119 | ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 155 |
| 12.4.6 | SPAIN | 155 |
| 12.4.6.1 | Rising awareness for early diagnosis of propel market | 155 |
| TABLE 120 | SPAIN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 156 |
| TABLE 121 | SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 156 |
| 12.4.7 | REST OF EUROPE | 157 |
| TABLE 122 | REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 157 |
| TABLE 123 | REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 157 |
| 12.5 | ASIA PACIFIC | 158 |
| FIGURE 30 | ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET SNAPSHOT | 158 |
| TABLE 124 | ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) | 159 |
| TABLE 125 | ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 159 |
| TABLE 126 | ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 160 |
| TABLE 127 | ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) | 160 |
| TABLE 128 | ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022-2029 (USD MILLION) | 160 |
| TABLE 129 | ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION) | 161 |
| TABLE 130 | ASIA PACIFIC: BACTERIAL SEPSIS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 161 |
| TABLE 131 | ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) | 161 |
| TABLE 132 | ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) | 162 |
| 12.5.1 | RECESSION IMPACT ON ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET | 162 |
| 12.5.2 | JAPAN | 162 |
| 12.5.2.1 | Rising incidence of pneumonia and infectious diseases to support market growth | 162 |
| TABLE 133 | JAPAN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 163 |
| TABLE 134 | JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 163 |
| 12.5.3 | CHINA | 164 |
| 12.5.3.1 | Healthcare infrastructure improvements to support market growth | 164 |
| TABLE 135 | CHINA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 164 |
| TABLE 136 | CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 165 |
| 12.5.4 | INDIA | 165 |
| 12.5.4.1 | Increasing patient population and rising number of surgical procedures to drive market | 165 |
| TABLE 137 | INDIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 166 |
| TABLE 138 | INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 166 |
| 12.5.5 | AUSTRALIA | 167 |
| 12.5.5.1 | Rapid growth in sepsis treatment procedures to propel market | 167 |
| TABLE 139 | AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 167 |
| TABLE 140 | AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 168 |
| 12.5.6 | SOUTH KOREA | 168 |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | |
|-----------|-------------------------------------------------------------------------------------------------|-----|
| 12.5.6.1 | Rising healthcare spending to support market growth | 168 |
| TABLE 141 | SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 169 |
| TABLE 142 | SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 169 |
| 12.5.7 | REST OF ASIA PACIFIC | 169 |
| TABLE 143 | REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 170 |
| TABLE 144 | REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 170 |
| 12.6 | LATIN AMERICA | 171 |
| TABLE 145 | LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) | 171 |
| TABLE 146 | LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 172 |
| TABLE 147 | LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 172 |
| TABLE 148 | LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) | 173 |
| TABLE 149 | LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022-2029 (USD MILLION) | 173 |
| TABLE 150 | LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION) | 173 |
| TABLE 151 | LATIN AMERICA: BACTERIAL SEPSIS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 174 |
| TABLE 152 | LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) | 174 |
| TABLE 153 | LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) | 174 |
| 12.6.1 | RECESSION IMPACT ON LATIN AMERICAN SEPSIS DIAGNOSTICS MARKET | 175 |
| 12.6.2 | BRAZIL | 175 |
| 12.6.2.1 | Investments by leading sepsis diagnostic manufacturers to support market growth | 175 |
| TABLE 154 | BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 175 |
| TABLE 155 | BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 176 |
| 12.6.3 | MEXICO | 176 |
| 12.6.3.1 | Rising medical tourism to drive market | 176 |
| TABLE 156 | MEXICO: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 177 |
| TABLE 157 | MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 177 |
| 12.6.4 | REST OF LATIN AMERICA | 177 |
| TABLE 158 | REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 178 |
| TABLE 159 | REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 178 |
| 12.7 | MIDDLE EAST & AFRICA | 179 |
| 12.7.1 | HIGH CONSUMPTION OF IMMUNE SYSTEM-SUPPRESSING MEDICATIONS TO PROPEL MARKET | 179 |
| TABLE 160 | MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022-2029 (USD MILLION) | 179 |
| TABLE 161 | MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 180 |
| TABLE 162 | MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 180 |
| TABLE 163 | MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) | 181 |
| TABLE 164 | MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022-2029 (USD MILLION) | 181 |
| TABLE 165 | MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION) | 181 |
| TABLE 166 | MIDDLE EAST & AFRICA: BACTERIAL SEPSIS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 182 |
| TABLE 167 | MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) | 182 |
| TABLE 168 | MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) | 182 |
| 12.7.2 | RECESSION IMPACT ON MIDDLE EAST & AFRICAN SEPSIS DIAGNOSTICS MARKET | 183 |
| 12.7.3 | GCC COUNTRIES | 183 |
| 12.7.3.1 | Developments in healthcare infrastructure to drive market | 183 |
| TABLE 169 | GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 183 |
| TABLE 170 | GCC COUNTRIES: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 184 |
| 12.7.4 | REST OF MIDDLE EAST & AFRICA | 184 |
| TABLE 171 | REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) | 184 |
| TABLE 172 | REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) | 185 |

| | | |
|-----------|----------------------------------------------------------------------------|-----|
| 13 | COMPETITIVE LANDSCAPE | 186 |
| 13.1 | INTRODUCTION | 186 |
| 13.2 | RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS | 186 |
| FIGURE 31 | SEPSIS DIAGNOSTICS MARKET: STRATEGIES ADOPTED | 187 |
| 13.3 | REVENUE SHARE ANALYSIS | 188 |
| FIGURE 32 | REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2020-2022 (USD MILLION) | 188 |
| 13.4 | MARKET SHARE ANALYSIS | 188 |
| 13.4.1 | SEPSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023 | 189 |
| FIGURE 33 | SEPSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023 | 189 |
| TABLE 173 | SEPSIS DIAGNOSTICS MARKET: DEGREE OF COMPETITION | 189 |
| 13.4.2 | BLOOD CULTURE MARKET SHARE, BY KEY PLAYER, 2023 | 190 |
| FIGURE 34 | BLOOD CULTURE MARKET SHARE, BY KEY PLAYER, 2023 | 190 |
| 13.4.3 | IMMUNOASSAY MARKET SHARE, BY KEY PLAYER, 2023 | 190 |
| FIGURE 35 | IMMUNOASSAYS MARKET SHARE, BY KEY PLAYER, 2023 | 190 |
| 13.4.4 | MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023 | 191 |
| FIGURE 36 | MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023 | 191 |
| 13.4.5 | BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023 | 191 |
| FIGURE 37 | BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023 | 191 |
| FIGURE 38 | SEPSIS DIAGNOSTICS MARKET RANKING (2023) | 192 |
| 13.5 | COMPANY EVALUATION MATRIX: KEY PLAYERS | 193 |
| 13.5.1 | STARS | 194 |
| 13.5.2 | EMERGING LEADERS | 194 |
| 13.5.3 | PERVASIVE PLAYERS | 194 |
| 13.5.4 | PARTICIPANTS | 194 |
| FIGURE 39 | SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 | 195 |
| 13.5.5 | COMPETITIVE FOOTPRINT | 196 |
| 13.5.5.1 | Overall company footprint | 196 |
| FIGURE 40 | SEPSIS DIAGNOSTICS MARKET: OVERALL COMPANY FOOTPRINT | 196 |
| 13.5.5.2 | Regional footprint | 197 |
| TABLE 174 | SEPSIS DIAGNOSTICS MARKET: REGIONAL FOOTPRINT | 197 |
| 13.5.5.3 | Technology footprint | 197 |
| TABLE 175 | SEPSIS DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT | 197 |
| 13.5.5.4 | Product footprint | 198 |
| TABLE 176 | SEPSIS DIAGNOSTICS MARKET: PRODUCT FOOTPRINT | 198 |
| 13.5.5.5 | Pathogen type footprint | 199 |
| TABLE 177 | SEPSIS DIAGNOSTICS MARKET: PATHOGEN TYPE FOOTPRINT | 199 |
| 13.6 | COMPANY EVALUATION MATRIX: STARTUPS/SMES | 200 |
| 13.6.1 | PROGRESSIVE COMPANIES | 200 |
| 13.6.2 | RESPONSIVE COMPANIES | 200 |
| 13.6.3 | DYNAMIC COMPANIES | 200 |
| 13.6.4 | STARTING BLOCKS | 200 |
| FIGURE 41 | SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 | 201 |
| 13.6.5 | COMPETITIVE BENCHMARKING | 202 |
| TABLE 178 | SEPSIS DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES | 202 |
| TABLE 179 | SEPSIS DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES | 202 |
| 13.7 | VALUATION AND FINANCIAL METRICS OF SEPSIS DIAGNOSTIC VENDORS | 203 |
| FIGURE 42 | EV/EBITDA OF KEY VENDORS | 203 |

FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 203

13.8 PRODUCT/BRAND COMPARATIVE ANALYSIS 204

FIGURE 44 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY MODEL (2023) 204

13.8.1 BIOMERIEUX 204

13.8.2 BECTON, DICKINSON AND COMPANY 204

13.8.3 F. HOFFMANN-LA ROCHE LTD. 205

13.8.4 DANAHER CORPORATION 205

13.8.5 QIAGEN N.V. 205

13.9 COMPETITIVE SCENARIO 205

13.9.1 PRODUCT LAUNCHES & APPROVALS 205

TABLE 180 SEPSIS DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2019-MARCH 2024 205

13.9.2 DEALS 206

TABLE 181 SEPSIS DIAGNOSTICS MARKET: DEALS, JANUARY 2019-MARCH 2024 206

13.9.3 EXPANSIONS 207

TABLE 182 SEPSIS DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2019-MARCH 2024 207

Sepsis Diagnostics Market Size By Technology (Microbiology, PCR, Immunoassay, microfluidics, Biomarker), Product (Media, Reagent, Instrument), Method (Automated), Test (Lab, POC), Pathogen (Bacterial, Fungal), End User & Region - Global Forecast to 2029

Market Report | 2024-04-08 | 264 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

| Select license | License | Price |
|----------------|-------------------------|------------|
| | Single User | \$4950.00 |
| | Multi User | \$6650.00 |
| | Corporate License | \$8150.00 |
| | Enterprise Site License | \$10000.00 |
| | | VAT |
| | | Total |

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

| | | | |
|---------------|----------------------|-------------------------------|----------------------|
| Email* | <input type="text"/> | Phone* | <input type="text"/> |
| First Name* | <input type="text"/> | Last Name* | <input type="text"/> |
| Job title* | <input type="text"/> | | |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/> |
| Address* | <input type="text"/> | City* | <input type="text"/> |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature